미국의 인간 1차 세포 배양 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Human Primary Cell Culture Market Growth & Trends:

The U.S. human primary cell culture market size is anticipated to reach USD 2.58 billion by 2030 and is anticipated to expand at a CAGR of 10.5% during the forecast period, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for precision medicine, advancements in cell culture technologies, and rising applications in drug discovery, regenerative medicine, and personalized healthcare.

The expanding applications in oncology and regenerative medicine are driving market growth. Primary cell cultures play a crucial role in cancer research by providing accurate models for studying tumor behavior and drug responses. In regenerative medicine, they are essential for developing stem cell therapies, tissue engineering, and regenerative treatments. Their ability to closely mimic human physiology enhances research efficiency, making them indispensable tools in advancing cancer therapies and personalized treatments, further fueling the market's expansion. Thereby propelling the demand for human primary cell culture in the U.S. over the forecast period.

The COVID-19 pandemic substantially boosted the demand for human primary cell culture in the U.S. market, driven by the urgent need for accurate models to study SARS-CoV-2 and develop vaccines and therapeutic treatments. Primary cell cultures became essential in virus research and drug development, enabling more reliable simulations of human responses. This surge in demand, coupled with increased investments in biomedical research, accelerated the adoption of primary cell cultures, positioning them as a key tool in both immediate and long-term healthcare solutions.

However, the high costs associated with primary cell culture media, reagents, and specialized equipment pose a significant market challenge. These expenses can limit the adoption of primary cell cultures, especially among smaller research institutions and biotech companies with constrained budgets. The ongoing need for premium-quality supplies and the complex setup for cell culture systems can further increase operational costs, making it difficult for less-funded entities to fully leverage these technologies. This cost barrier could slow the market's growth and reduce accessibility to advanced research models.

U.S. Human Primary Cell Culture Market Report Highlights:

• The primary cells segment held the largest market share of 35.08% in 2024. This is attributed to their essential role in drug discovery, toxicity testing, and personalized medicine development across various research applications. However, primary cell culture media is anticipated to grow at the fastest CAGR over the forecast period
• The therapy development segment dominated the application market in 2024, driven by the increasing use of primary cell cultures in drug development, personalized treatments, and the advancement of targeted therapies. However, regenerative medicine is anticipated to grow at the fastest CAGR over the forecast period
• The pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 49.27% in 2024. However, CMOs & CROs are expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic and infectious diseases
    • 3.2.1.2. Growing focus on personalized medicine
    • 3.2.1.3. Technological innovations in 3D cell culture
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs of primary cells
• 3.3. U.S. Human Primary Cell Culture Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Human Primary Cell Culture Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. U.S. Human Primary Cell Culture Market Product Movement Analysis
• 4.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Primary Cells
  • 4.4.1. Primary Cells Market, 2018 - 2030 (USD Million)
  • 4.4.2. Hematopoietic Cells
    • 4.4.2.1. Hematopoietic Cells Market, 2018 - 2030 (USD Million)
  • 4.4.3. Skin Cells
    • 4.4.3.1. Skin Cells Market, 2018 - 2030 (USD Million)
  • 4.4.4. Hepatocytes
    • 4.4.4.1. Hepatocytes Market, 2018 - 2030 (USD Million)
  • 4.4.5. Gastrointestinal Cells
    • 4.4.5.1. Gastrointestinal Cells Market, 2018 - 2030 (USD Million)
  • 4.4.6. Lung Cells
    • 4.4.6.1. Lung Cells Market, 2018 - 2030 (USD Million)
  • 4.4.7. Renal Cells
    • 4.4.7.1. Renal Cells Market, 2018 - 2030 (USD Million)
  • 4.4.8. Heart Cells
    • 4.4.8.1. Heart Cells Market, 2018 - 2030 (USD Million)
  • 4.4.9. Skeletal and Muscle Cells
    • 4.4.9.1. Skeletal and Muscle Cells Market, 2018 - 2030 (USD Million)
  • 4.4.10. Other Primary Cells
    • 4.4.10.1. Other Primary Cells Market, 2018 - 2030 (USD Million)
• 4.5. Reagents & Supplements
  • 4.5.1. Reagents & Supplements Market, 2018 - 2030 (USD Million)
  • 4.5.2. Serum-free Media
    • 4.5.2.1. Serum-free Media Market, 2018 - 2030 (USD Million)
  • 4.5.3. Serum-containing Media
    • 4.5.3.1. Serum-containing Media Market, 2018 - 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)
• 4.6. Primary Cell Culture Media
  • 4.6.1. Primary Cell Culture Media Market, 2018 - 2030 (USD Million)
  • 4.6.2. Attachment Solutions
    • 4.6.2.1. Attachment Solutions Market, 2018 - 2030 (USD Million)
  • 4.6.3. Buffers and Salts
    • 4.6.3.1. Buffers and Salts Market, 2018 - 2030 (USD Million)
  • 4.6.4. Sera
    • 4.6.4.1. Sera Market, 2018 - 2030 (USD Million)
  • 4.6.5. Growth Factors and Cytokines
    • 4.6.5.1. Growth Factors and Cytokines Market, 2018 - 2030 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Human Primary Cell Culture Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. U.S. Human Primary Cell Culture Market Application Movement Analysis
• 5.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Discovery
  • 5.4.1. Drug Discovery Market, 2018 - 2030 (USD Million)
• 5.5. Therapy Development
  • 5.5.1. Therapy Development Market, 2018 - 2030 (USD Million)
• 5.6. Regenerative Medicine
  • 5.6.1. Regenerative Medicine Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Human Primary Cell Culture Market: End Use Estimates & Trend Analysis

• 6.1. End Use Segment Dashboard
• 6.2. U.S. Human Primary Cell Culture Market End Use Movement Analysis
• 6.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 6.5. CMOs & CROs
  • 6.5.1. CMOs & CROs Market, 2018 - 2030 (USD Million)
• 6.6. Academic Research Institutes
  • 6.6.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
• 7.3. Company Profiles/Listing
  • 7.3.1. Thermo Fisher Scientific, Inc.
    • 7.3.1.1. Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Product Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. Merck KGaA
    • 7.3.2.1. Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Product Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Lonza Group
    • 7.3.3.1. Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Product Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Corning Incorporated
    • 7.3.4.1. Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Danaher Corporation
    • 7.3.5.1. Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. QIAGEN N.V.
    • 7.3.6.1. Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. STEMCELL Technologies
    • 7.3.7.1. Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Becton, Dickinson, and Company (BD)
    • 7.3.8.1. Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Bio-Techne Corporation
    • 7.3.9.1. Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Charles River Laboratories
    • 7.3.10.1. Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives